What intra‑articular injection medications are recommended for an adult with non‑infectious knee pain?

Intra-articular Knee Injection Medications for Non-Infectious Knee Pain

For adults with non-infectious knee pain, intra-articular corticosteroid injections are the primary recommended injectable therapy, with hyaluronic acid as a conditional second-line option for knee osteoarthritis only after other treatments have failed. 1, 2

Primary Recommendation: Corticosteroid Injections

Corticosteroid injections have the strongest evidence (Level 1A+) for both osteoarthritis and rheumatoid arthritis of the knee, providing significant pain relief and functional improvement lasting months to one year 3. The 2021 EULAR guidelines and 2020 ACR/Arthritis Foundation guidelines both support their use 1, 2, 4.

Key Implementation Points:

• Preferred agent: Triamcinolone hexacetonide offers advantages over triamcinolone acetonide and should be the corticosteroid of choice (Level 2B+) 3
• Frequency limitation: Avoid more than 3-4 injections in the same joint per year 1
• Timing considerations: Perform at least 3 months prior to joint replacement surgery if planned (infection risk increases from 0.5% to 1.0% if injected within 3 months of surgery) 1

Critical Safety Precautions:

• Diabetic patients: Monitor glucose levels closely days 1-3 post-injection due to transient hyperglycemia risk 1
• Prosthetic joints: Avoid routine use; only consider after strict infection screening by orthopedic surgeons (0.6% infection rate reported) 1
• Post-injection activity: Avoid overuse for 24 hours but do not immobilize the joint 1

Conditional Second-Line: Hyaluronic Acid (Knee Only)

Hyaluronic acid for knee osteoarthritis receives a conditional recommendation against from ACR/AF guidelines, though EULAR and other international guidelines are more favorable 2, 4. This creates a nuanced clinical decision point.

The Evidence Conflict:

The ACR/AF 2020 guideline conditionally recommends against hyaluronic acid because when limited to low-risk-of-bias trials, the effect size approaches zero compared to saline 2. However, the guideline explicitly states this conditional recommendation "is consistent with the use of hyaluronic acid injections, in the context of shared decision-making...when other alternatives have been exhausted or failed" 2.

Recent 2025 data shows hyaluronic acid was associated with decreased OA progression at MRI for up to 2 years post-injection (mean WORMS difference -0.42, P=0.003), while corticosteroids showed greater progression 5. This represents important new evidence favoring hyaluronic acid for disease modification, not just symptom relief.

When to Consider Hyaluronic Acid:

• After failure of corticosteroids, NSAIDs, and non-pharmacologic therapies
• Patients with significant surgical risk factors
• Mild radiographic disease where conservative treatment failed
• May provide longer pain relief than corticosteroids (Level 2B+) 3
• Repeated courses show sustained pain reduction without serious adverse effects 1

Strongly Recommended Against:

• Hyaluronic acid in the hip: Strong recommendation against (higher quality evidence of lack of benefit) 2

Strongly Recommended Against (All Have Strong Evidence of Inefficacy or Harm):

Do not use the following intra-articular injections 2:

• Platelet-rich plasma (PRP): Strong recommendation against (lack of standardization, heterogeneous preparations)
• Stem cell injections: Strong recommendation against (lack of standardization, safety concerns)
• Botulinum toxin: Conditional recommendation against (small trials suggest lack of efficacy)
• Prolotherapy: Conditional recommendation against (small effect sizes, variable protocols)
• TNF inhibitors and IL-1 receptor antagonists: Strong recommendation against (no demonstrated efficacy, known toxicity risks)

Important Caveat on Research vs. Guidelines:

While one 2021 network meta-analysis suggested stromal vascular fraction (SVF) had the highest P-scores for pain and function 6, this is not supported by any major clinical practice guidelines and involves highly experimental, non-standardized preparations. Stick with guideline-recommended therapies in clinical practice.

Clinical Algorithm:

1. First-line injectable: Intra-articular corticosteroid (triamcinolone hexacetonide preferred)

   • Limit to 3-4 injections per year
   • Screen for diabetes, check timing if surgery planned

2. If inadequate response or contraindication to corticosteroids: Consider hyaluronic acid for knee OA only

   • Discuss limited evidence with patient
   • Document shared decision-making
   • Not for hip OA

3. Avoid all other injectable therapies listed above due to lack of efficacy or standardization